3Yalamanchili K, Fleisher AG, Lehrman SG, et al. Open pulmonary embolectomy for treatnlent of major pulmonary embolism. Ann Thorae Surg, 2004,77:819-823.
4Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. Blood Rev, 2005, 19 : 179-202.
5PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d' Embolie Pulmonaire par Interruption Cave) randomized study. Circulation, 2005,112:416-422.
6Karmy-Jones R, Jurkovich GJ, Velmahos GC, et al. Practice patterns and outcomes of retrievable vena cava filters in trauma patients : an AAST multicenter study. J Trauma, 2007,62 : 17-24.
7Barral FG. Vena cava filters: why, when, what and how? J Cardiovasc Surg (Torino) , 2008,49:35-49.
8Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism : a European nmlticenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol, 1992, 19:239-245.
9Dalla-Volta S, Palla A, Santolicandro A, et al. PALMS 2: aheplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol, 1992, 20:520-526.
10Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest, 1990, 98: 1473-1479.
